LONDON (ShareCast) - (Sharecast News) - Hikma Pharmaceuticals' US subsidiary has launched a generic equivalent to Pfizer's Halcion tablets for insomnia.
Hikma Pharmaceuticals USA has launched Triazolam tablets, 0.125mg and 0.25mg, which are indicated for the short-term treatment of insomnia - generally seven to 10 days.

According to pharmaceutical information group IQVIA, US sales of Triazolam tablets came to around $27m in the year to the end of September 2018.

Brian Hoffmann, president of Hikma's generics division, said: "We are excited to launch Triazolam tablets, improving patients' access to this product. This launch highlights the successful execution of our strategy to develop more differentiated products by leveraging our specialised manufacturing capabilities."

At 1100 GMT, the shares were down 1.1% to 1,720.50p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE